Particularly, in some embodiments, hydrophilic active agents are released more quickly, e.g., approximately 50% of drug release after 24 hours, the remainder released over approximately 5 days, whereas hydrophobic agents are released more slowly, e.g., approximately 80% after 8 weeks
All patients with BO should be taking life-long acid-suppressant therapy, preferably a PPI once a day
As opposed to other antioxidants, it does not merely battle alone
Patients should consult their doctor if they experience allergic reactions or unusual symptoms
Avatrombopag (a novel analog of eltrombopag), which has shown efficacy in preliminary studies on thrombocytopenia associated with liver disease (Terrault 2012), is being tested in chronic immune thrombocytopenia patients (ClinicalTrials.gov 2012b)